PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation
PurposeThe inhibition of immune checkpoints such as programmed cell death ligand-1 (PD-L1/CD274) with antibodies is providing novel opportunities to expose cancer cells to the immune system. Antibody based checkpoint blockade can, however, result in serious autoimmune complications because normal ti...
Main Authors: | Jesus Pacheco-Torres, Marie-France Penet, Balaji Krishnamachary, Yelena Mironchik, Zhihang Chen, Zaver M. Bhujwalla |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.614365/full |
Similar Items
-
The PD-L1 metabolic interactome intersects with choline metabolism and inflammation
by: Jesus Pacheco-Torres, et al.
Published: (2021-02-01) -
Biomimetic Nanoparticles Camouflaged in Cancer Cell Membranes and Their Applications in Cancer Theranostics
by: Jiefu Jin, et al.
Published: (2020-01-01) -
Degradable Dextran Nanopolymer as a Carrier for Choline Kinase (ChoK) siRNA Cancer Therapy
by: Zhihang Chen, et al.
Published: (2016-02-01) -
Water and Collagen Content Are High in Pancreatic Cancer: Implications for Quantitative Metabolic Imaging
by: Marie-France Penet, et al.
Published: (2021-01-01) -
Ascites Volumes and the Ovarian Cancer Microenvironment
by: Marie-France Penet, et al.
Published: (2018-12-01)